Clinical Trials Directory

Trials / Unknown

UnknownNCT05658055

The Effect of Probiotics on Gut Microbiotain After Helicobacter Pylori Eradication

The Effect of Probiotics With Vonoprazan-amoxicillin Dual Therapy on Gut Microbiotain After Helicobacter Pylori Eradication: A Randomized Controlled Trial

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Nanjing First Hospital, Nanjing Medical University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the effect of probiotics during vonoprazan-amoxicillin dual therapy on the gut microbiota in Helicobacter pylori eradication and to investigate whether the eradication rate of H.pylori will be improved when adding probiotics

Detailed description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirement will be included in this simultaneous blind test. A total of 100 patients with HP infection were enrolled in this study. All patients were randomly divided into two groups according to the ratio of 1:1. Group A was given vonoprazan 20mg bid, amoxicillin 1000mg tid, Probiotics 3tabltes tid for 14 consecutive days; Group B was given vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days. On the 14th days of treatment, the researchers will follow up the patients' adverse reactions and medication compliance. The feces of the subjects were collected one day before the treatment, and on the 14th and 42th days after the treatment; After 4 weeks of drug withdrawal, all subjects will be reexamined with 13C-UBT.

Conditions

Interventions

TypeNameDescription
DRUGVonoprazanPotassium-competitive acid blocker
DRUGAmoxicillinAntibiotic for H. pylori eradication
DRUGprobioticsMedilac-S; Enterococcus faecium 4.5\*10\^8 and Bacillus subtilis 5.0\*10\^7, Hanmi,Beijing, China

Timeline

Start date
2023-06-01
Primary completion
2023-12-31
Completion
2023-12-31
First posted
2022-12-20
Last updated
2023-02-08

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05658055. Inclusion in this directory is not an endorsement.